Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -591.60% is 243% below its 4-year average of -172.39%, near the low end of its 4-year range (-591.60%–-24.97%).
As of the fiscal period ended Tuesday, June 30, 2026. 106.85% below its 12-month average of -286.01%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -591.60%.
RETURN ON EQUITY (ROE)
-591.60%
RETURN ON EQUITY (ROE) AVG TTM
-286.01%
RETURN ON EQUITY (ROE) AVG 3Y
-207.14%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-106.85%
CURRENT VS 3Y AVG
-185.61%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-1308.23%
vs the sector median at left
Nexalin Technology, Inc.
Market Cap
$3.54M
Return on Equity (ROE)
-591.60%
TTM Avg
-286.01%
3Y Avg
-207.14%
5Y Avg
N/A
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.60M
Return on Equity (ROE)
-5.85%
TTM Avg
-5.85%
3Y Avg
-10.40%
5Y Avg
7.36%
Market Cap
$3.46M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
Market Cap
$3.64M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.72M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$3.79M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.28M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | $3.54M | -591.60% | -286.01% | -207.14% | N/A |
| Eocene Ltd. (EOCN)vs › | $3.54M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.60M | -5.85% | -5.85% | -10.40% | 7.36% |
| Moolec Science S.A. (MLEC)vs › | $3.46M | -89.85% | 30.83% | -183.24% | -146.59% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | -282.13% | -313.25% | -153.55% | -153.55% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.72M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | -40.75% | -35.89% | -218.64% | -156.11% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.22M | -133.43% | -203.84% | -174.81% | -140.61% |
ROE
-591.6%
ROA
-299.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -591.60% |
| 2026-03-31 | -288.63% |
| 2025-12-31 | -219.38% |
| 2025-09-30 | -182.01% |
| 2025-06-30 | -148.42% |
| 2025-03-31 | -367.87% |
| 2024-12-31 | -206.94% |
| 2024-09-30 | -112.04% |
| 2024-06-30 | -399.96% |
| 2024-03-31 | -212.35% |
| 2023-12-31 | -144.97% |
| 2023-09-30 | -142.05% |
| 2023-06-30 | -61.00% |
| 2023-03-31 | -43.84% |
| 2022-12-31 | -31.41% |
| 2022-09-30 | -24.97% |
